Federal Circuit Partially Confirms Longer Patent Terms Under Exelixis and Novartis

by Wilson Sonsini Goodrich & Rosati

On January 15, 2014, the U.S. Court of Appeals for the Federal Circuit1 confirmed that patent owners may be entitled to extended patent terms, a finding that is especially important for select pharmaceutical, biotech, and medical device patents where extending patent life can result in significant additional revenue. Specifically, the court partially upheld two district court decisions from the Eastern District of Virginia2 and the District of Columbia,3 ruling in part against the U.S. Patent and Trademark Office (USPTO) regarding patent term adjustment (PTA) length calculations.

The USPTO is legally required to increase a patent's lifetime to compensate for undue delays in "[p]atent term guarantees" that are covered under 35 U.S.C. § 154(b)(1), including: "(A) Guarantee of prompt patent and trademark office responses," "(B) Guarantee of no more than 3-year application pendency," and "(C) Guarantee of adjustments for delays due to derivation proceedings, secrecy orders, and appeals." The potential increase in patent length is calculated by determining whether the USPTO has gone beyond time periods allowed. At issue in both the district courts and Federal Circuit was the determination of whether "B" delays were properly calculated by the USPTO.

In both Exelixis and Novartis, the parties challenged the USPTO's interpretation of guarantee (B), i.e., Congress' goal to limit patent application pendency to three years. § 154(b)(1)(B) provides for a day-for-day extension of patent term for every day beyond three years after a patent application's filing date until the patent issues, except for "time consumed by continued examination of the application requested by the applicant" and other listed exceptions.4 The USPTO historically has taken the position that requesting continued examination (RCE) of a patent application after three years from the patent application's filing date tolls the day-for-day increase in patent lifetime.

The district courts in Exelixis and Novartis found that the USPTO had been incorrectly applying the law where continued examinations were requested after the three-year period had passed. Instead, the district courts ruled that RCEs filed after the three-year period had passed did not toll the day-for-day increase in patent term. On appeal, the USPTO made two arguments: 1) under 35 U.S.C. § 154(b)(1)(B)(i), no adjustment time is available for "any time consumed by continued examination" regardless of when continued examination is initiated; and 2) "time consumed by continued examination" includes the time period between allowance of the application and issuance of the patent.

While conceding that when read "in isolation, [§ 154(b)(1)(B)] might be read, as two district courts have read it," the Federal Circuit ultimately agreed with the USPTO that the proper interpretation, taking the statute as a whole, is "that the patent term adjustment time should be calculated by determining the length of time between application and patent issuance, then subtracting any continued examination time [and any other time excluded in the statute] . . . and determining the extent to which the result exceeds three years."5 Thus, the court agreed with the USPTO and partially rejected the Novartis and Exelixis district court findings that included all continued examination time filed after the three-year time period of § 154(b)(1)(B) in PTA calculations.

However, the Federal Circuit disagreed with the USPTO's interpretation of "time consumed by continued examination" as including the time period between allowance and issuance after a continued examination request is made. The court found that the period between allowance and issuance does not fall within an "examination" period since "'examination' presumptively ends at allowance."6 The court thus "attribute[ed] this time to the PTO," resulting in the inclusion of the time period between allowance and issuance in calculating PTA adjustment even where continued examination had been requested.

The practical effect of the Federal Circuit's ruling means that the extended time periods are likely not as long as calculated following the district court rulings in Novartis and Exelixis. However, the court did affirm extended patent terms where an RCE was filed as including the time period between a notice of allowance and issuance of the patent. Depending upon the timing of payment of the issue fee and actual issuance of the patent, this time period could potentially add upwards of 4 to 6+ months of extended patent term.

Moreover, unlike in Novartis and Exelixis, a day-for-day extension of patent term could apply to patents where an RCE was filed just prior to the three-year post-filing date, if the time period between receipt of a notice of allowance and actual issuance of the patent would bring the calculation of patent prosecution pendency past the three-year mark under 35 U.S.C. § 154(b)(1)(B).

While the findings may yet be appealed by the USPTO, patent owners should consider the following actions:

  1. If a patent application is pending and the applicant is considering filing an RCE, it may be advisable to wait to submit an RCE as close to or after the three-year mark from the application's filing date in order to maximize PTA (assuming no extensions of time are taken).
  2. If a patent application is allowed after the filing of an RCE close to or after the three-year mark from the application's filing date, it may be prudent to wait as long as possible (up to three months) to pay the issue fee—again, in order to maximize PTA.
  3. For patents that were recently issued or that will issue in the near term, patent owners should consider filing a petition requesting reconsideration of the PTA calculated by the USPTO to appropriately extend their patent term. Petitions must be filed with the PTO within 2 months from issuance.

Quick action is required to preserve the right to increased PTA; otherwise, increased PTA could be lost.7

1 Novartis AG v. Lee, No. 2013-1160 and 2013-1179 (Fed. Cir. Jan. 15, 2014) at http://www.cafc.uscourts.gov/images/stories/opinions-orders/13-1160.Opinion.1-13-2014.1.PDF and Exelixis, Inc. v. Lee, 2013-1175 (Fed. Cir. Jan. 15, 2014) at http://www.cafc.uscourts.gov/images/stories/opinions-orders/13-1175.Opinion.1-13-2014.1.PDF.

2 Exelixis, Inc. v. Kappos, 906 F. Supp. 2d 474 (E.D. Va. 2012).

3 Novartis AG v. Kappos, 904 F. Supp. 2d 58 (D.D.C. 2012).

4 See 35 U.S.C. §§ 154(b)(1)(B)(i)-(iii).

5 Novartis at 13.

6 Id. at 15.

7 Note that the Federal Circuit confirmed the finding in Novartis regarding the limited statutory period in which to pursue an appeal of PTA findings under 35 U.S.C. § 154(b)(4). The time period of 180 days after grant under § 154(b)(4) (which is tolled if a request for reconsideration is made by the applicant under § 154(b)(3)) is strictly construed by the courts. See Novartis at 9-11.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Wilson Sonsini Goodrich & Rosati | Attorney Advertising

Written by:

Wilson Sonsini Goodrich & Rosati

Wilson Sonsini Goodrich & Rosati on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.